CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the ac…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push CeriBell (NASDAQ:CBLL) outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base. Speaking at Canaccord’s 46th Annual Global Growth Conf | ||
CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ... Strong growth driven by new FDA clearances, Delirium NTAP approval, and expanding account base despite widening net losses. | ||
 CeriBell, Inc. Q2 2026 Earnings Call Summary Moby summary of CeriBell, Inc.'s Q2 2026 earnings call | ||
 CeriBell (CBLL) Q2 2026 Earnings Call Transcript Revenue surged 33% as hospital accounts expanded and delirium reimbursement neared launch. | ||
 Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. | ||
 CeriBell Q2 Earnings Call Highlights CeriBell (NASDAQ:CBLL) reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring | ||
 CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of -13.33% and +3.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates QuidelOrtho (QDEL) delivered earnings and revenue surprises of +425.00% and +2.65%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 CeriBell Shares Gain After Medicare Approves Additional Payment for Delirium Monitoring System CeriBell Inc. (NASDAQ:CBLL) shares climbed about 3% after the company announced that the U. | ||
IInsider Monkey | ||